Gilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls for lower drug prices because of spiralling healthcare costs.
Gilead recorded a loss of $3.9 billion in Q4 because of a one-off charge linked to US tax reforms – however it has bigger problems because of the decline in its hepatitis C portfolio.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.